all report title image
  • Published In : May 2024
  • Code : CMI2656
  • Pages :178
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Key Developments

  • On January 5, 2024, Theravance Biopharma, Inc., a pharmaceutical company, announced results from the Phase 4 PIFR-2 study of YUPELRI (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD. The PIFR-2 study aimed to demonstrate greater improvement in lung function for YUPELRI delivered via standard jet nebulizer as compared to Spiriva (tiotropium) delivered via a dry powder inhaler (Spiriva HandiHaler) in adults with severe to very severe COPD and suboptimal peak inspiratory flow rate (PIFR).
  • In November 2023, Lupin, a pharmaceutical company, announced the launch of Vilfuro-G, the world's first fixed-dose triple combination drug (FDC) for the treatment of chronic obstructive pulmonary disease (COPD) in India. Vilfuro-G is available in a single-strength fixed dose, with a recommended once-daily dosage for the treatment of COPD, which refers to a group of diseases that cause airflow blockage and breathing-related problems.
  • In November 2023, Alkem, a pharmaceutical company, announced a COPD awareness campaign that focuses on promoting healthy lungs and the role of inhalation therapy. The campaign spans the country, aiming to educate the public and ensure efforts against respiratory diseases. The campaign urges employers to create safe breathing environments, citizens to promote air cleanliness, and supports research for improved care access
  • In May 2021, TrialSpark Inc., a tech-enabled drug development company, announced a collaboration with Sanofi, a global biopharmaceutical company, to accelerate COPD clinical development. TrialSpark's technology-enabled clinical trial platform is uniquely equipped to run challenging trials faster and more efficiently by increasing patient access to investigational medicines and dramatically expediting patient recruitment timelines

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Reliability and Reputation


Reliability and Reputation


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.